Small conjugate-based theranostic agents: an encouraging approach for cancer therapy
Top Cited Papers
- 29 June 2015
- journal article
- review article
- Published by Royal Society of Chemistry (RSC) in Chemical Society Reviews
- Vol. 44 (19), 6670-6683
- https://doi.org/10.1039/c5cs00224a
Abstract
We review the latest developments on small conjugate based theranostic agents for tumor treatment and diagnosis using fluorescence and magnetic resonance imaging (MRI).Keywords
This publication has 49 references indexed in Scilit:
- Histone‐Deacetylase‐Targeted Fluorescent Ruthenium(II) Polypyridyl Complexes as Potent Anticancer AgentsChemistry – A European Journal, 2013
- Thiol-inducible direct fluorescence monitoring of drug releaseOrganic & Biomolecular Chemistry, 2013
- Molecular and Cellular Characterization of the Biological Effects of Ruthenium(II) Complexes Incorporating 2-Pyridyl-2-pyrimidine-4-carboxylic AcidJournal of the American Chemical Society, 2012
- Molecular Imaging with Theranostic NanoparticlesAccounts of Chemical Research, 2011
- Cell-Specific, Activatable, and Theranostic Prodrug for Dual-Targeted Cancer Imaging and TherapyJournal of the American Chemical Society, 2011
- Boronate Oxidation as a Bioorthogonal Reaction Approach for Studying the Chemistry of Hydrogen Peroxide in Living SystemsAccounts of Chemical Research, 2011
- Chemistry and biology of reactive oxygen species in signaling or stress responsesNature Chemical Biology, 2011
- Synthesis and Characterization of a Theranostic Vascular Disrupting Agent for In Vivo MR ImagingBioconjugate Chemistry, 2011
- Prodrug-based intracellular delivery of anticancer agentsAdvanced Drug Delivery Reviews, 2011
- Biological Evaluation of a Novel Doxorubicin−Peptide Conjugate for Targeted Delivery to EGF Receptor-Overexpressing Tumor CellsMolecular Pharmaceutics, 2011